Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24128024 | 1.00 | DYRK1A (0.35) | DYRK1AHPGDKDM4ENPC1PKM | |
| SCHEMBL24128140 | 0.88 | DYRK1A (0.35) | DYRK1AHPGDKDM4ENPC1PKM | |
| SCHEMBL24634066 | 0.88 | HPGD (0.38) | DYRK1AHPGDKDM4ENPC1PKM | |
| SCHEMBL24128040 | 0.88 | DYRK1A (0.32) | DYRK1AHPGD | |
| SCHEMBL29720546 | 0.88 | DYRK1A (0.32) | DYRK1AHPGD | |
| SCHEMBL24128091 | 0.87 | DYRK1A (0.34) | DYRK1AHPGD | |
| SCHEMBL29720605 | 0.87 | HPGD (0.42) | DYRK1AHPGDNPC1RAB9A | |
| SCHEMBL24128030 | 0.87 | HPGD (0.42) | DYRK1AHPGDNPC1RAB9A | |
| SCHEMBL24127726 | 0.84 | NPC1 (0.43) | DYRK1AHPGDKDM4ENPC1RAB9A | |
| SCHEMBL29720442 | 0.84 | NPC1 (0.43) | DYRK1AHPGDKDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240309015-A1 | Methods for the Treatment of Fibrotic Disease | SHY THERAPEUTICS, LLC | 2024-09-19 | — | — | US | disclosed |
| US-20240124483-A1 | Methods for the Treatment of Fibrotic Disease | SHY THERAPEUTICS, LLC | 2024-04-18 | — | — | US | disclosed |
| EP-4284377-A1 | METHODS FOR THE TREATMENT OF FIBROTIC DISEASE | Shy Therapeutics LLC (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC | 2023-07-20 | — | — | US | disclosed |
| EP-4168414-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | Shy Therapeutics LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| WO-2022165000-A1 | METHODS FOR THE TREATMENT OF FIBROTIC DISEASE | SHY THERAPEUTICS, LLC (US) | 2022-08-04 | — | — | WO | disclosed |
| WO-2022164997-A1 | METHODS FOR THE TREATMENT OF FIBROTIC DISEASE | SHY THERAPEUTICS, LLC (US) | 2022-08-04 | — | — | WO | disclosed |
| WO-2021257828-A9 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC (US) | 2022-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124483-A1 | Methods for the Treatment of Fibrotic Disease | SMAD3, SMAD2, MAPK3 | DYRK1A 3415/4885HPGD 2101/4885KDM4E 2935/4885 |
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | KRAS, G3BP1, NRAS | DYRK1A 4292/4885HPGD 1303/4885KDM4E 3454/4885 |
| US-20240309015-A1 | Methods for the Treatment of Fibrotic Disease | SMAD3, SMAD2, MAPK3 | DYRK1A 3368/4885HPGD 2014/4885KDM4E 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.